Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis

JACC: Cardiovascular Imaging

Volumn 4, Issue 6, 2011, Pages 659-670

  Rapezzi, Claudio ^a   Quarta, Candida C ^a   Guidalotti, Pier Luigi ^a   Pettinato, Cinzia ^a   Fanti, Stefano ^a   Leone, Ornella ^a   Ferlini, Alessandra ^b   Longhi, Simone ^a   Lorenzini, Massimiliano ^a   Reggiani, Letizia Bacchi ^a   Gagliardi, Christian ^a   Gallo, Pamela ^a   Villani, Caterina ^a   Salvi, Fabrizio ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c BELLARIA HOSPITAL   (Italy)

Author keywords

99mTc DPD scintigraphy; cardiac amyloidosis; diagnosis; hereditary transthyretin related amyloidosis; prognosis

Indexed keywords

ALANINE; GLYCINE; PREALBUMIN; PROLINE; TECHNETIUM 99M; THREONINE;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; ECHOCARDIOGRAPHY; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE WALL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; SCINTIGRAPHY; UNIVARIATE ANALYSIS;

ADULT; AGED; AMYLOIDOSIS, FAMILIAL; BIOPSY; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; ECHOCARDIOGRAPHY, DOPPLER, PULSED; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIUM; ORGANOTECHNETIUM COMPOUNDS; PREALBUMIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR FUNCTION, LEFT;

EID: 79958804438     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2011.03.016     Document Type: Article

References (42)

1. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-62. (Pubitemid 41043725)
2. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-23. (Pubitemid 47512065)
3. Rapezzi C, Perugini E, Salvi F, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006;13: 143-53.
4. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52: 347-61.
5. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
6. Selvanayagam JB, Hawkins PN, Paul B, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101-10. (Pubitemid 350117349)
7. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009; 120:1203-12.
8. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14: 3219-30.
9. Glaudemans AW, Slart RH, Zeebregts CJ, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging 2009;36:702-14.
10. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2- propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005 20;46:1076-84.
11. Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:4708.
12. Arbustini E, Verga L, Concardi M, et al. Electron and immunoelectron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002;9:108-14. (Pubitemid 34787804)
13. Benson MD, Breall J, Cummings OW, Liepnieks JJ. Biochemical characterisation of amyloid by endomyocardial biopsy. Amyloid 2009;16:9-14.
14. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005; 79:319-28. (Pubitemid 41098849)
15. Ferlini A, Fini S, Salvi F, et al. Molecular strategies in genetic diagnosis of transthyretin-related hereditary amyloidosis. FASEB J 1992;6:2864-6.
16. Surawicz B, Knilans TK. Chou's Electrocardiography in Clinical Practice. 5th edition. Philadelphia, PA: WB Saunders, 2001.
17. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol. 2003;42:954-70.
18. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8. (Pubitemid 16119719)
19. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998;32: 865-75. (Pubitemid 28459571)
20. Hazenberg BP, van Rijswijk MH, Lub-de Hooge MN, et al. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 2007; 48:865-72. (Pubitemid 46909912)
21. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508-13. (Pubitemid 20260051)
22. Hawkins P. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002;11: 649-55. (Pubitemid 35440848)
23. Aprile C, Marinone G, Saponaro R, et al. Cardiac and pleuropulmonary. AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 1995;22:1393-401. (Pubitemid 26002917)
24. Han S, Chong V, Murray T, et al. Preliminary experience of 99mTc-aprotinin scintigraphy in amyloidosis. Eur J Haematol 2007;79:494-500. (Pubitemid 350126671)
25. Schaadt BK, Hendel HW, Gimsing P, et al. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med 2003;44: 177-83.
26. Hongo M, Urushibata K, Kai R, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 2002;144:122-9. (Pubitemid 34734765)
27. Tanaka M, Hongo M, Kinoshita O, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1997; 29:168-74. (Pubitemid 27028735)
28. Leinonen H, Tötterman KJ, Korppi-Tommola T, Korhola O. Negative myocardial technetium-99m pyrophosphate scintigraphy in amyloid heart disease associated with type AA systemic amyloidosis. Am J Cardiol 1984;53:380-1. (Pubitemid 14215412)
29. Eriksson P, Backman C, Bjerle P, et al. Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br Heart J 1984;52:321-6.
30. Worsley DF, Lentle BC. Uptake of technetium-99m MDP in primary amyloidosis with a review of the mechanisms of soft tissue localization of bone seeking radiopharmaceuticals. J Nucl Med 1993;34:1612-5. (Pubitemid 23254362)
31. Ak I, Vardareli E, Erdinc O, et al. Myocardial Tc-99m MDP uptake on a bone scan in senile systemic amyloidosis with cardiac involvement. Clin Nucl Med 2000;25:826-7.
32. Puille M, Altland K, Linke RP, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol 2002;29:376-9. (Pubitemid 34253251)
33. Kulhanek J, Movahed A. Uptake of technetium 99m HDP in cardiac amyloidosis. Int J Cardiovasc Imaging 2003;19:225-7. (Pubitemid 36705697)
34. Tsang W, Lang RM. Echocardiographic evaluation of cardiac amyloid. Curr Cardiol Rep 2010;12:272-6.
35. Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004;43:410-5. (Pubitemid 38167701)
36. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111:186-93. (Pubitemid 40139730)
37. Bellavia D, Pellikka PA, Abraham TP, et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 2008;101:1039-45.
38. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003;107:2446-52. (Pubitemid 36605227)
39. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59. (Pubitemid 24370135)
40. Merlini G, Palladini G. Amyloidosis: is a cure possible? Ann Oncol 2008; 19:63-6.
41. Klein AL, Hatle LK, Burstow DJ, et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1989;13:1017-26. (Pubitemid 19091289)
42. Herlenius G, Wilczek HE, Larsson M, et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004; 77:64-71. (Pubitemid 38116874)